№ files_lp_3_process_9_50677
File format: docx Character count: 6992 File size: 154 KB
Year: 2026
Region / city: Not specified
Topic: Guselkumab treatment for pediatric plaque psoriasis
Document type: Research study
Institution: Not specified
Author: Vimal H. Prajapati, Marieke M.B. Seyger, Dagmar Wilsmann-Theis, Erzsebet Szakos, Andrzej Kaszuba, Bart van Hartingsveldt, Meg Jett, Gigi Jiang, Shu Li, Vikash Sinha, Herta Crauwels, Cynthia M.C. DeKlotz, Amy S. Paller
Target audience: Healthcare professionals, dermatologists
Study period: Not specified
Date of approval: Not specified
Date of revisions: Not specified
Description: Phase 3, randomized, placebo-controlled study of Guselkumab for pediatric patients with moderate-to-severe plaque psoriasis.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Dupilumab efficacy in patients with uncontrolled moderate-to-severe type 2 asthma regardless of perennial aeroallergen sensitization
Year: 2023
Region / City: Multiple countries
Topic: Medical / Asthma Treatment
Document Type: Research Study
Organization / Institution: Various research centers and universities
Authors: Jonathan Corren, David J. Jackson, Thomas B. Casale, Larry Borish, Klaus F. Rabe, William W. Busse, Jorge F. Maspero, Daniel J. Jackson, Nadia Daizadeh, Arman Altincatal, Amr Radwan, Angela Khodzhayev, Michel Djandji, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz
Target Audience: Medical professionals, researchers
Period of Validity: Ongoing study
Date of Approval: N/A
Date of Amendments: N/A
Authorization for treatment with TREMFYA® (guselkumab)
Year: [Insert Year]
Region / City: [Insert City, State ZIP]
Theme: Medical Treatment Authorization
Document Type: Authorization Request
Organization: [Insert Payer Name]
Author: [Insert Healthcare Provider’s Name]
Target Audience: Medical Director or individual responsible for prior authorization
Period of Validity: [Insert Date Range if Applicable]
Approval Date: [Insert Date if Available]
Amendment Date: [Insert Date if Applicable]
GUSELKUMAB, Solution for injection 100 mg in 1 mL pen device, Tremfya®, Janssen-Cilag Pty Ltd
Year: 2020
Region / City: Australia
Topic: Pharmaceutical Benefits Scheme (PBS) listing
Document Type: Committee Submission
Agency: PBAC (Pharmaceutical Benefits Advisory Committee)
Author: Committee Secretariat
Target Audience: Healthcare professionals, PBAC members
Period of Effect: From May 13, 2020
Approval Date: May 13, 2020
Modification Date: Not specified
Authorization for treatment with TREMFYA® (guselkumab)
Year: [Insert Year]
Region / City: [Insert City, State]
Topic: Medical treatment authorization
Document Type: Letter
Organization / Institution: [Insert Institution Name]
Target Audience: Medical Director / Payer
Period of Effectiveness: [Insert period if specified]
Approval Date: [Insert Date]
Amendment Date: [Insert Date if applicable]
Topics: PROTOSTAR moderate-to-severe guselkumab